EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506

Gene expression profiling predicts clinical outcome of breast cancer

van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536

Ki67 expression in breast cancer

Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775

Cancer Statistics, 2003

Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275

The polycomb group protein EZH2 is involved in progression of prostate cancer

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717

Diseases of the Breast

Haagenson, C. (1971) · Cited by 1,773

Genetic and epigenetic alterations in breast cancer: What are the perspectives for clinical practice?

Fucito, A., Lucchetti, C., Giordano, A., & Romano, G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.10.018 · Cited by 29

HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells

Ganai, S. A., Kalladi, S. M., & Mahadevan, V. (2014) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2014.938247 · Cited by 28

High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas

Ramaglia, M., D’Angelo, V., Iannotta, A., Pinto, D., Pota, E., Affinita, M. C., Donofrio, V., Errico, M. E., Lombardi, A., Indolfi, C., et al. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0338-x · Cited by 28

Epigenetic Regulation of Breast Cancer Stem Cells Contributing to Carcinogenesis and Therapeutic Implications

Wu, H., & Chu, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158113 · Cited by 29

Chromatin Structure Regulation in Transforming Growth Factor-β-Directed Epithelial-Mesenchymal Transition

Blumenberg, M., Gao, S., Dickman, K. G., Grollman, A. P., Böttinger, E. P., & Zavadil, J. (2007) · Cells Tissues Organs · doi:10.1159/000101317 · Cited by 28

hMOF (human males absent on the first), an oncogenic protein of human oral tongue squamous cell carcinoma, targeting EZH2 (enhancer of zeste homolog 2)

Li, Q., Sun, H., Shu, Y., Zou, X., Zhao, Y., & Cheng, G. (2015) · Cell Proliferation · doi:10.1111/cpr.12177 · Cited by 27

MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2

Zeng, W.-H., Zou, G., Cao, X.-L., & Li, W.-Z. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1160-z · Cited by 41

Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients

Zhao, X., Yang, X., Fu, L., & Yu, K. (2021) · Cancer Management and Research · doi:10.2147/cmar.s276422 · Cited by 27

Chemical biology and pharmacology of histone lysine methylation inhibitors

Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 29

Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression

Davoodi, N. A., Najafi, S., Ghale-Noie, Z. N., Piranviseh, A., Mollazadeh, S., Asouri, S. A., Asemi, Z., Morshedi, M., Zadeh, S. S. T., Hamblin, M. R., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1065837 · Cited by 27

Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors

Lanzi, C., Arrighetti, N., Pasquali, S., & Cassinelli, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115727 · Cited by 27

Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor

Miner, S. J., & Alarid, E. T. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-263 · Cited by 27

Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target

Li, H., & Zhang, R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00047 · Cited by 27

Therapeutic prospects for epigenetic modulation

Heightman, T. D. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.561786 · Cited by 27

Hsp90 as a “Chaperone” of the Epigenome

Isaacs, J. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.09.003 · Cited by 28

Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence

Huang, J. M., Chikeka, I., & Hornyak, T. J. (2016) · Dermatologic Clinics · doi:10.1016/j.det.2016.08.001 · Cited by 29

Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer

Huang, Y., Tao, T., Liu, C., Guan, H., Zhang, G., Ling, Z., Zhang, L., Lǚ, K., Chen, S., Xu, B., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3840 · Cited by 27

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells

Momparler, R. L., Côté, S., Momparler, L. F., & Idaghdour, Y. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00019 · Cited by 27

Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex

Wang, X., Hua, Y., Xu, G., Deng, S., Yang, D., & Gao, X. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s189871 · Cited by 27

The role of lidocaine in cancer progression and patient survival

Chida, K., Kanazawa, H., Kinoshita, H., Roy, A. M., Hakamada, K., & Takabe, K. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108654 · Cited by 26

H3K27me3-mediated epigenetic regulation in pluripotency maintenance and lineage differentiation

Jiang, L., Huang, L., & Jiang, W. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100180 · Cited by 24

An overview of the development of EED inhibitors to disable the PRC2 function

Liu, K., Zhu, K., & Zhang, H. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00274k · Cited by 27

Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells

Yao, F., Zhan, Y., Li, C., Lu, Y., Chen, J., Deng, J., Wu, Z., Li, Q., Song, Y., Chen, B., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.734287 · Cited by 26

Crucial Roles of LncRNAs-Mediated Autophagy in Breast Cancer

Han, X., Mo, J., Yang, Y., Wang, Y., & Lu, H. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.72621 · Cited by 26

Epigenetic Regulations in Mammalian Cells: Roles and Profiling Techniques

Kim, U., & Lee, D.-S. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.0013 · Cited by 27

Carcinogenicity of nicotine and signal pathways in cancer progression: a review

Rao, Z., Xu, Y., He, Z., Wang, J., Ji, H., Zhang, Z., Zhou, J., Zhou, T., & Wang, H. (2023) · Environmental Chemistry Letters · doi:10.1007/s10311-023-01668-1 · Cited by 26

Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention

Shen, C., & Vakoc, C. R. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000151 · Cited by 26

Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2

Wang, S., Zhu, Y., He, H., Liu, J., Xu, L., Zhang, H., Liu, H., Liu, W., Liu, Y., Pan, D., et al. (2013) · Cancer Science · doi:10.1111/cas.12132 · Cited by 26

PLU1 histone demethylase decreases the expression of KAT5 and enhances the invasive activity of the cells

Yoshida, M., Ishimura, A., Terashima, M., Enkhbaatar, Z., Nozaki, N., Satou, K., & Suzuki, T. (2011) · Biochemical Journal · doi:10.1042/bj20110343 · Cited by 26

Cross-species analyses unravel the complexity of H3K27me3 and H4K20me3 in the context of neural stem progenitor cells

Rhodes, C. T., Sandstrom, R. S., Huang, S.-W. A., Wang, Y., Schotta, G., Berger, M. S., & Lin, C. A. (2016) · Neuroepigenetics · doi:10.1016/j.nepig.2016.04.001 · Cited by 26

Gene Perturbation Atlas (GPA): a single-gene perturbation repository for characterizing functional mechanisms of coding and non-coding genes

Xiao, Y., Gong, Y., Lv, Y., Lan, Y., Hu, J. R., Li, F., Xu, J., Bai, J., Deng, Y., Liu, L., et al. (2015) · Scientific Reports · doi:10.1038/srep10889 · Cited by 26

EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms

Venkatesan, N., Wong, J. F., Tan, K. P., Chung, H. H., Yau, Y. H., Cukuroglu, E., Allahverdi, A., Nordenskiöld, L., Göke, J., Shochat, S. G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.309 · Cited by 29

Chromatin modifiers and carcinogenesis

Gregory, R., & Shiekhattar, R. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.10.002 · Cited by 27

EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features

Liu, Y., Yu, K., Li, M., Zeng, K., Wei, J., Li, X., Liu, Y., Zhao, D., Fan, L., Yu, Z., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.04.011 · Cited by 25

Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer

Ma, L., Yan, Y., Bai, Y., Yang, Y., Pan, Y., Gang, X., Karnes, R. J., Zhang, J., Lv, Q., Wu, Q., et al. (2019) · Theranostics · doi:10.7150/thno.34700 · Cited by 27

Covalent inhibitors of EZH2: Design, synthesis and evaluation

Zhang, Q., Chen, X., Hu, X., Duan, X., Wan, G., Li, L., Feng, Q., Zhang, Y., Wang, N., & Yu, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112617 · Cited by 26

Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways

Liu, L., Xiao, B., Hirukawa, A., Smith, H. W., Zuo, D., Sanguin‐Gendreau, V., McCaffrey, L. M., Nam, A. J., & Muller, W. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303010120 · Cited by 26

EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3

Tang, B., Du, J., Li, Y., Tang, F., Wang, Z., & He, S. (2014) · Medical Oncology · doi:10.1007/s12032-014-0271-6 · Cited by 25

Epigenetic therapy of hematological malignancies: where are we now?

Popovic, R., Shah, M. Y., & Licht, J. D. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712466864 · Cited by 26

BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells

Nishioka, C., Ikezoe, T., Yang, J., & Yokoyama, A. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.03.012 · Cited by 25

Rnf2 knockdown reduces cell viability and promotes cell cycle arrest in gastric cancer cells

Zhang, J., Sun, Z., Han, Y., Yao, R., Yue, L., Xu, Y. H., & Zhang, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.5868 · Cited by 26

microRNA‑214 suppresses the growth of cervical cancer cells by targeting EZH2

Yang, Y., Liu, Y., Li, G., Li, L., Geng, P., & Song, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9363 · Cited by 25

Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors

Wassef, M. A., Michaud, A., & Margueron, R. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1208872 · Cited by 25

Links between Serine Biosynthesis Pathway and Epigenetics in Cancer Metabolism

Kim, H., & Park, Y. J. (2018) · Clinical Nutrition Research · doi:10.7762/cnr.2018.7.3.153 · Cited by 25

Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis

Jayaraj, R., Raymond, G., Krishnan, S., Tzou, K. S., Baxi, S., Ram, M. R., Govind, S. K., Chandramoorthy, H. C. K., Abu-Khzam, F. N., & Shaw, P. M. (2020) · Cancers · doi:10.3390/cancers12051199 · Cited by 24

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib

Yu, Y., Liao, H., Xie, R., Zhang, Y., Zheng, R., Chen, J., & Zhang, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590813 · Cited by 24

H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes

Day, C. A., Hinchcliffe, E. H., & Robinson, J. (2022) · Cells · doi:10.3390/cells11213376 · Cited by 24

An EZH2-NF-κB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer

Dardis, G., Wang, J., Simon, J. M., Wang, G. G., & Baldwin, A. S. (2023) · iScience · doi:10.1016/j.isci.2023.107115 · Cited by 25

Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations

Kreike, B., Hart, G. A. M., Bartelink, H. G. M. M., & van de Vijver, M. J. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0588-6 · Cited by 24

Oncoprotein E7 from Beta Human Papillomavirus 38 Induces Formation of an Inhibitory Complex for a Subset of p53-Regulated Promoters

Saidj, D., Cros, M., Hernández‐Vargas, H., Guarino, F., Sylla, B. S., Tommasino, M., & Accardi, R. (2013) · Journal of Virology · doi:10.1128/jvi.01047-13 · Cited by 24

Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer

Thanapprapasr, D., Hu, W., Sood, A. K., & Coleman, R. L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800626201 · Cited by 24

Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray

Guo, J., Gong, G.-H., & Zhang, B. (2017) · Tumor Biology · doi:10.1177/1010428317713392 · Cited by 24

Opposite Effects of SET7/9 on Apoptosis of Human Acute Myeloid Leukemia Cells and Lung Cancer Cells

Gu, Y., Wang, Y., Xl, W., Gao, L., Yu, W., & Dong, W.-F. (2017) · Journal of Cancer · doi:10.7150/jca.19143 · Cited by 24

EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma

Lian, R., Ma, H., Wu, Z., Zhang, G., Jiao, L., Miao, W., Jin, Q., Li, R., Chen, P., Shi, H., et al. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3133-7 · Cited by 24

Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer

Cascio, S., Faylo, J., Sciurba, J. C., Jia, X., Ranganathan, S., Lohmueller, J. J., Beatty, P. L., & Finn, O. J. (2017) · Oncotarget · doi:10.18632/oncotarget.22168 · Cited by 24

EZH 2 overexpression in head and neck cancer is related to lymph node metastasis

Nienstedt, J. C., Schroeder, C., Clauditz, T. S., Simon, R., Sauter, G., Muenscher, A., Blessmann, M., Hanken, H., & Pflug, C. (2017) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12673 · Cited by 24

Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells

Mellini, P., Marrocco, B., Borovika, D., Polletta, L., Carnevale, I., Saladini, S., Stazi, G., Zwergel, C., Trapencieris, P., Ferretti, E., et al. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0150 · Cited by 24

GSK343 induces autophagy and downregulates the AKT/mTOR signaling pathway in pancreatic cancer cells

Xu, H., Zhang, L., Qian, X., Zhou, X., Yan, Y., Zhou, J., Ge, W., Albahde, M. A. H., & Wang, W. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7845 · Cited by 24

Synthesis and Assays of Inhibitors of Methyltransferases

Cai, X.-C., Kapilashrami, K., & Luo, M. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.01.009 · Cited by 24

Differential proteomic alterations between localised and metastatic prostate cancer

Taylor, B. S., Varambally, S., & Chinnaiyan, A. M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603274 · Cited by 24

Beyond the tail: the consequence of context in histone post-translational modification and chromatin research

Weinzapfel, E. N., Fedder-Semmes, K. N., Sun, Z., & Keogh, M. (2024) · Biochemical Journal · doi:10.1042/bcj20230342 · Cited by 23

EZH2 directly methylates PARP1 and regulates its activity in cancer

Meng, Q., Shen, J., Ren, Y., Liu, Q., Wang, R., Li, Q., Jiang, W., Wang, Q., Zhang, Y., Trinidad, J. C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl2804 · Cited by 24

Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer

Michalak, E. M., & Jonkers, J. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9199-z · Cited by 23

Enhancer of Zeste Homolog 2 Expression Is Associated With Tumor Cell Proliferation and Invasion in Cervical Cancer

Fang, J., Li, Q., & Zhang, M. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821335a9 · Cited by 23

Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro

He, S.-B., Zhou, H., Zhou, J., Zhou, G.-Q., Han, T., Wan, D.-W., Gu, W., Gao, L., Zhang, Y., Xue, X.-F., et al. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214542215 · Cited by 23

Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2

Lachat, C., Boyer‐Guittaut, M., Peixoto, P., & Hervouet, É. (2018) · Epigenomes · doi:10.3390/epigenomes3010001 · Cited by 27

Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery

Li, Y., Yang, G., Yang, C., Tang, P., Chen, J., Zhang, J., Liu, J., & Ouyang, L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00579 · Cited by 23

RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity

Touboul, R., Baritaki, S., Zaravinos, A., & Bonavida, B. (2021) · Cancers · doi:10.3390/cancers13246247 · Cited by 24

Epigenetic and Transcriptional Signaling in Ewing Sarcoma—Disease Etiology and Therapeutic Opportunities

Li, M., & Chen, C.-W. D. (2022) · Biomedicines · doi:10.3390/biomedicines10061325 · Cited by 23

Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis

Casanova, A. G., Roth, G. S., Hausmann, S., Lu, X., Bischoff, L. J. M., Froeliger, E. M., Belmudes, L., a-Flin, E. B., Flores, N. M., Benitez, A. M., et al. (2024) · Cell Discovery · doi:10.1038/s41421-023-00644-x · Cited by 23

Polycomb and the Emerging Epigenetics of Pancreatic Cancer

Grzenda, A. L., Ördög, T., & Urrutia, R. A. (2011) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-011-9262-4 · Cited by 25

Regulation of DU145 prostate cancer cell growth by Scm-like with four mbt domains 2

Lee, K., Na, W., Maeng, J.-H., Wu, H., & Ju, B. (2012) · Journal of Biosciences · doi:10.1007/s12038-012-9283-6 · Cited by 23

A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma

Paolicchi, E., Pacetti, P., Giovannetti, E., Mambrini, A., Orlandi, M., Crea, F., Romani, A. A., Tartarini, R., Danesi, R., Peters, G. J., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1559 · Cited by 23

The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth

Setoguchi (2010) · Oncology Reports · doi:10.3892/or_00000684 · Cited by 23

Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma

Nakagawa, S., Okabe, H., Ouchi, M., Tokunaga, R., Umezaki, N., Higashi, T., Kaida, T., Arima, K., Kitano, Y., Kuroki, H., et al. (2018) · HPB · doi:10.1016/j.hpb.2018.03.018 · Cited by 23

Deregulacja mechanizmów epigenetycznych w nowotworach Marta Maleszewska*,

Maleszewska, M., Wojtaś, B., & Kamińska, B. (2018) · Postępy Biochemii · doi:10.18388/pb.2018_125 · Cited by 23

Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation

Denkiewicz, M., Saha, I., Rakshit, S., Sarkar, J. P., & Plewczyński, D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01047 · Cited by 23

High methylation levels of histone H3 lysine 9 associated with activation of hypoxia-inducible factor 1α (HIF-1α) predict patients’ worse prognosis in human hepatocellular carcinomas

Qian, Y., Li, Y., Zheng, C., Lu, T., Sun, R., Mao, Y., Yu, S., Fan, H., & Zhang, Z. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.04.077 · Cited by 23

Epigenetic Silencing of miR-9 Promotes Migration and Invasion by EZH2 in Glioblastoma Cells

Chien, Y., Chen, J., Chen, Y.-H., Chou, R., Lee, H.-C., & Yu, Y. (2020) · Cancers · doi:10.3390/cancers12071781 · Cited by 23

Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

Leitner, K., Tsibulak, I., Wieser, V. E., Knoll, K., Reimer, D., Marth, C., Fiegl, H., & Zeimet, A. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-77532-x · Cited by 24

Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer

Bachmann, N., Hoegel, J. J., Haeusler, J., Kuefer, R., Herkommer, K., Paiss, T., Vogel, W., & Maier, C. (2005) · The Prostate · doi:10.1002/pros.20296 · Cited by 23

High expression of heparanase-2 is an independent prognostic parameter for favorable survival in gastric cancer patients

Zhang, X., Shu, X., Tan, Q., & Liu, L. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.09.012 · Cited by 23

Epigenetic regulation in adult stem cells and cancers

Tarayrah, L., & Chen, X. (2013) · Cell & Bioscience · doi:10.1186/2045-3701-3-41 · Cited by 22

Epigenetic regulation in cancer development

Caffarelli, E. (2011) · Frontiers in bioscience · doi:10.2741/3880 · Cited by 23

Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression

Kopparapu, P. K., Bhoi, S., Mansouri, L., Arabanian, L. S., Plevová, K., Pospı́šilová, Š., Wasik, A. M., Croci, G. A., Sander, B., Paulli, M., et al. (2016) · Epigenetics · doi:10.1080/15592294.2016.1164375 · Cited by 22

Combination of BMP2 and EZH2 Inhibition to Stimulate Osteogenesis in a 3D Bone Reconstruction Model

Lui, H., Samsonraj, R. M., Vaquette, C., Denbeigh, J. M., Kakar, S., Cool, S. M., Dudakovic, A., & van Wijnen, A. J. (2020) · Tissue Engineering Part A · doi:10.1089/ten.tea.2020.0218 · Cited by 22

Treating human cancer by targeting EZH2

Xu, M., Xu, C., Wang, R., Tang, Q., Zhou, Q., Wu, W., Wan, X., Mo, H., Pan, J., & Wang, S. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101313 · Cited by 25

DNA Methylation and Histone Modifications in Breast Cancer

Dumitrescu, R. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-612-8_3 · Cited by 22

Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors

Zhang, L., Song, X., Wang, N., Zhao, L., Feng, Q., You, X., Peng, C., Gao, T., Xiong, M., He, B., et al. (2015) · RSC Advances · doi:10.1039/c5ra02365c · Cited by 22

Promises and challenges of anticancer drugs that target the epigenome

Verbrugge, I., Johnstone, R. W., & Bots, M. L. (2011) · Epigenomics · doi:10.2217/epi.11.82 · Cited by 22

EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells

Stefánsson, Ó. A., & Esteller, M. (2011) · Breast Cancer Research · doi:10.1186/bcr2871 · Cited by 22

Relationship Between Noncoding RNA Dysregulation and Epigenetic Mechanisms in Cancer

Suzuki, H., Maruyama, R., Yamamoto, E., Niinuma, T., & Kai, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-1498-7_4 · Cited by 22

Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines

Feng, H., Sheppard, H., Wu, G., Davidoff, A. M., & Yang, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25484 · Cited by 22

PCAT-1: A pivotal oncogenic long non-coding RNA in human cancers

Yang, Z., Zhao, S., Zhou, X., Zhao, H., & Jiang, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.014 · Cited by 22

The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion

Cho, K. H., Jeong, B. Y., Park, C. G., & Lee, H. Y. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01149-6 · Cited by 22

p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.

Yang, P., Hong, Y.-H., Hsu, K., & Liu, T. (2019) · PubMed Central · Cited by 22

EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers

Zheng, X., Li, W., Yi, J., Liu, J.-Y., Ren, L., Zhu, X., Liu, S.-W., Wang, J., & Du, G. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00543-x · Cited by 22

PRC2 regulates RNA polymerase III transcribed non-translated RNA gene transcription through EZH2 and SUZ12 interaction with TFIIIC complex

Liu, C., Li, S., Dai, X., Ma, J., Wan, J., Jiang, H., Wang, P., Liu, Z., & Zhang, H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv574 · Cited by 22

The Role of Polycomb Group Protein EZH2 in Cancer Progression.

Cao, Q. (2008)

Abstract 5309: Understanding the function of EZH2 as a determinant of breast cancer invasion and metastasis

Moore, H. M., Gonzalez, M. E., Daniels, C. N., Li, X., Toy, K. A., & Kleer, C. G. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-5309

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Collett, K., Eide, G. E., Arnes, J. B., Stefansson, I. M., Eide, J., Braaten, A. O., Aas, T., Otte, A. P., & Akslen, L. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1533 · Cited by 272

The Role of EZH2 in Breast Cancer Progression and Metastasis.

Moore, H. M. (2013) · Deep Blue (University of Michigan) · Cited by 2

Understanding the Function of EZH2 as a Determinant of Breast Cancer Invasion and Metastasis

Moore, H. K., & Kleer, C. G. (2013) · doi:10.21236/ada578212